On page 39, please delete "AD" and insert --autoimmune diseases-- in place

On page 41, line 3, please delete "AD" and insert --autoimmune diseases-- in place therefor.

In the Claims:

herefor.

Please cancel claims 33-58, without prejudice.

Please add new claims 59-67 as follows:

- 59. A method of treating Acquired Immunodeficiency Disease in a patient comprising administering to said patient an effective amount of a plurality of at least two autoimmune inhibitors selected from the group donsisting of an antibody to alpha interferon, an antibody to alpha interferon receptor, alpha interferon receptor, an antibody to gamma interferon, an antibody to gamma interferon receptor, gamma interferon receptor, an antibody to tumor necrosis factor receptor, tumor necrosis factor receptor, an antibody to an HLA class II antigen, an antibody to an HLA class II antigen receptor.
- 60. The method of claim 59, wherein said plurality of autoimmune inhibitors comprises (a) at least one autoimmune inhibitor selected from the group consisting of an antibody to alpha interferon, an antibody to alpha interferon receptor and alpha interferon receptor, and (b) at least one autoimmune inhibitor selected from the group consisting of an antibody to gamma interferon, an antibody to gamma interferon receptor and gamma interferon receptor.
- 61. The method of claim 60, wherein said plurality of autoimmune inhibitors further comprises at least one of an autoimmune inhibitor selected from the group consisting of an antibody to tumor necrosis factor, an antibody to tumor necrosis factor receptor and tumor necrosis factor receptor.
- 62. The method of claim 61, wherein said plurality of autoimmune inhibitors further comprises an autoimmune inhibitor selected from the group consisting of at least one of an antibody to an HLA class II antigen, an antibody to an HLA class II antigen receptor and an HLA class II antigen receptor.

- 63. The method of claim 59, wherein said antibody is selected from the group consisting of a monoclonal antibody, a polyclonal antibody, and combinations thereof, including biologically active fragments, functional equivalents, derivatives, or allelic or species variants thereof.
- 64. The method of claim 59, wherein an effective amount of beta interferon is also administered to said patient.
- 65. The method of claim 59, wherein said plurality of autoimmune inhibitors further comprises an autoimmune inhibitor selected from the group consisting of an antibody to interleukin 6, an antibody to interleukin 6 receptor and interleukin 6 receptor.
- 66. A method of treating Acquired Immunodeficiency Disease in a patient comprising administering to said patient an autoimmune inhibitor selected from the group consisting of an antibody to gamma interferon, an antibody to gamma interferon receptor and a gamma interferon receptor in an amount effective to neutralize or reduce fluid activity levels of gamma interferon.
- 67. A method of treating Acquired Immunodeficiency Disease in a patient comprising administering to said patient an autoimmune inhibitor selected from the group consisting of an antibody to an HLA class II antigen, an antibody to an HLA class II antigen receptor and an HLA class II antigen receptor in an amount effective to neutralize or reduce fluid activity levels of <u>said</u> HLA class II antigen.

Remarks

Claims 59-67 are pending in the application.

Applicants have amended the specification in order to clarify and correct minor typographical and editing errors in the specification and to more accurately claim that which Applicants regard as their invention. Support for each of the amendments to the specification is found in the specification as discussed herein and thus, no new matter has been added by way of these amendments.

The specification has been amended on pages 2, 3, 5, 8, 10 and 17 to make minor clarifications in the text. Further, the term "AD" has been deleted throughout the specification and has been replaced with either the phrase --autoimmune disease-- or the phrase --autoimmune